Shin SJ - Search Results

1

Effect of Itraconazole, a Potent CYP3A4 Inhibitor, on the Steady-State Pharmacokinetics of Vemurafenib in Patients With BRAF^V600 Mutation-Positive Malignancies.

Zhang W, Mathisen M, Goodman GR, Forbes H, Song Y, Bertran E, Demidov L, Shin SJ. Zhang W, et al. Among authors: shin sj. Clin Pharmacol Drug Dev. 2021 Jan;10(1):39-45. doi: 10.1002/cpdd.822. Epub 2020 Jun 29. Clin Pharmacol Drug Dev. 2021. PMID: 32602215 Clinical Trial.

2

Randomized, Double-Blind, Placebo-Controlled, Global Phase III Trial of Talimogene Laherparepvec Combined With Pembrolizumab for Advanced Melanoma.

Chesney JA, Ribas A, Long GV, Kirkwood JM, Dummer R, Puzanov I, Hoeller C, Gajewski TF, Gutzmer R, Rutkowski P, Demidov L, Arenberger P, Shin SJ, Ferrucci PF, Haydon A, Hyngstrom J, van Thienen JV, Haferkamp S, Guilera JM, Rapoport BL, VanderWalde A, Diede SJ, Anderson JR, Treichel S, Chan EL, Bhatta S, Gansert J, Hodi FS, Gogas H. Chesney JA, et al. Among authors: shin sj. J Clin Oncol. 2023 Jan 20;41(3):528-540. doi: 10.1200/JCO.22.00343. Epub 2022 Aug 23. J Clin Oncol. 2023. PMID: 35998300 Free PMC article. Clinical Trial.

3

Belotecan for relapsing small-cell lung cancer patients initially treated with an irinotecan-containing chemotherapy: a phase II trial.

Jeong J, Cho BC, Sohn JH, Choi HJ, Kim SH, Lee YJ, Jung MK, Shin SJ, Park MS, Kim SK, Chang J, Kim JH. Jeong J, et al. Among authors: shin sj. Lung Cancer. 2010 Oct;70(1):77-81. doi: 10.1016/j.lungcan.2010.01.006. Epub 2010 Mar 16. Lung Cancer. 2010. PMID: 20138389 Clinical Trial.

4

Salvage chemotherapy of biweekly irinotecan plus S-1 (biweekly IRIS) in previously treated patients with advanced gastric cancer.

Chon HJ, Rha SY, Park HS, Shin SJ, Kim HS, Roh JK, Noh SH, Chung HC, Jeung HC. Chon HJ, et al. Among authors: shin sj. Cancer Chemother Pharmacol. 2011 Oct;68(4):991-9. doi: 10.1007/s00280-011-1560-9. Epub 2011 Feb 16. Cancer Chemother Pharmacol. 2011. PMID: 21327684 Free PMC article. Clinical Trial.

5

A randomized phase 2 study of docetaxel and S-1 versus docetaxel and cisplatin in advanced gastric cancer with an evaluation of SPARC expression for personalized therapy.

Jeung HC, Rha SY, Im CK, Shin SJ, Ahn JB, Yang WI, Roh JK, Noh SH, Chung HC. Jeung HC, et al. Among authors: shin sj. Cancer. 2011 May 15;117(10):2050-7. doi: 10.1002/cncr.25729. Epub 2010 Nov 29. Cancer. 2011. PMID: 21523716 Free article. Clinical Trial.

6

A phase I pharmacokinetic study of TSU-68 (a multiple tyrosine kinase inhibitor of VEGFR-2, FGF and PDFG) in combination with S-1 and oxaliplatin in metastatic colorectal cancer patients previously treated with chemotherapy.

Shin SJ, Jung M, Jeung HC, Kim HR, Rha SY, Roh JK, Chung HC, Ahn JB. Shin SJ, et al. Invest New Drugs. 2012 Aug;30(4):1501-10. doi: 10.1007/s10637-011-9683-8. Epub 2011 May 13. Invest New Drugs. 2012. PMID: 21567184 Clinical Trial.

7

Results of a Phase II Study to Evaluate the Efficacy of Docetaxel and Carboplatin in Metastatic Malignant Melanoma Patients Who Failed First-Line Therapy Containing Dacarbazine.

Lee CK, Jung M, Choi HJ, Kim HR, Kim HS, Roh MR, Ahn JB, Chung HC, Heo SJ, Rha SY, Shin SJ. Lee CK, et al. Among authors: shin sj. Cancer Res Treat. 2015 Oct;47(4):781-9. doi: 10.4143/crt.2014.261. Epub 2015 Feb 16. Cancer Res Treat. 2015. PMID: 25687848 Free PMC article. Clinical Trial.

8

Open-label, phase IIa study of dabrafenib plus trametinib in East Asian patients with advanced BRAF V600-mutant cutaneous melanoma.

Si L, Zhang X, Shin SJ, Fan Y, Lin CC, Kim TM, Dechaphunkul A, Maneechavakajorn J, Wong CS, Ilankumaran P, Lee DY, Gasal E, Li H, Guo J. Si L, et al. Among authors: shin sj. Eur J Cancer. 2020 Aug;135:31-38. doi: 10.1016/j.ejca.2020.04.044. Epub 2020 Jun 10. Eur J Cancer. 2020. PMID: 32534242 Clinical Trial.

9

ARAF mutations confer resistance to the RAF inhibitor belvarafenib in melanoma.

Yen I, Shanahan F, Lee J, Hong YS, Shin SJ, Moore AR, Sudhamsu J, Chang MT, Bae I, Dela Cruz D, Hunsaker T, Klijn C, Liau NPD, Lin E, Martin SE, Modrusan Z, Piskol R, Segal E, Venkatanarayan A, Ye X, Yin J, Zhang L, Kim JS, Lim HS, Kim KP, Kim YJ, Han HS, Lee SJ, Kim ST, Jung M, Hong YH, Noh YS, Choi M, Han O, Nowicka M, Srinivasan S, Yan Y, Kim TW, Malek S. Yen I, et al. Among authors: shin sj. Nature. 2021 Jun;594(7863):418-423. doi: 10.1038/s41586-021-03515-1. Epub 2021 May 5. Nature. 2021. PMID: 33953400 Clinical Trial.

10

Phase II study of erlotinib in advanced non-small-cell lung cancer after failure of gefitinib.

Cho BC, Im CK, Park MS, Kim SK, Chang J, Park JP, Choi HJ, Kim YJ, Shin SJ, Sohn JH, Kim H, Kim JH. Cho BC, et al. Among authors: shin sj. J Clin Oncol. 2007 Jun 20;25(18):2528-33. doi: 10.1200/JCO.2006.10.4166. J Clin Oncol. 2007. PMID: 17577030 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

1,788 results

Search Page